We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.87%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$833M
AUM Growth
+$240M
Cap. Flow
+$158M
Cap. Flow %
18.98%
Top 10 Hldgs %
35.14%
Holding
103
New
14
Increased
42
Reduced
34
Closed
7

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$19.1M
2
UNH icon
UnitedHealth
UNH
+$11.9M
3
COO icon
Cooper Companies
COO
+$7.39M
4
ESRX
Express Scripts Holding Company
ESRX
+$6.9M
5
MDT icon
Medtronic
MDT
+$6.56M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$4.81M
2
OCR
OMNICARE INC
OCR
+$3.85M
3
GILD icon
Gilead Sciences
GILD
+$3.17M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$3.01M
5
MCK icon
McKesson
MCK
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 76.95%
2 Financials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOLX
76
DELISTED
Hologic
HOLX
$3.54M 0.43%
93,000
-8,000
-8% -$280K
PTLA
77
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.46M 0.42%
+76,000
New +$3.06M
ATXS
78
DELISTED
Astria Therapeutics
ATXS
$3.24M 0.39%
+4,424
New +$3.34M
EPZM
79
DELISTED
Epizyme, Inc
EPZM
$3.16M 0.38%
+131,785
New +$2.54M
CPHD
80
DELISTED
Cepheid Inc
CPHD
$3.12M 0.37%
51,000
-1,000
-2% -$57K
CMRX
81
DELISTED
Chimerix, Inc.
CMRX
$3.05M 0.37%
66,000
+51,800
+365% +$2.08M
TSRO
82
DELISTED
TESARO, Inc.
TSRO
$2.99M 0.36%
50,899
-2,100
-4% -$120K
RIGL icon
83
Rigel Pharmaceuticals
RIGL
$750M
$2.97M 0.36%
92,500
-7,500
-8% -$287K
DVAX
84
DELISTED
Dynavax Technologies
DVAX
$2.88M 0.35%
122,835
– –
OMCL icon
85
Omnicell
OMCL
$1.68B
$2.79M 0.34%
74,000
-6,000
-8% -$219K
PODD icon
86
Insulet
PODD
$9.79B
$2.79M 0.33%
90,000
– –
ELGX
87
DELISTED
Endologix Inc
ELGX
$2.75M 0.33%
17,900
-1,500
-8% -$248K
ARRY
88
DELISTED
Array Biopharma Inc
ARRY
$2.67M 0.32%
370,000
-30,000
-8% -$221K
ADVM
89
DELISTED
Adverum Biotechnologies
ADVM
$2.5M 0.3%
15,401
+11,101
+258% +$3.75M
ACHN
90
DELISTED
Achillion Pharmaceuticals
ACHN
$2.48M 0.3%
280,000
– –
TNDM icon
91
Tandem Diabetes Care
TNDM
$1.56B
$2.27M 0.27%
20,900
– –
MRTX
92
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.57M 0.19%
50,000
+4,612
+10% +$136K
LXRX icon
93
Lexicon Pharmaceuticals
LXRX
$1.1B
$1.38M 0.17%
170,915
-56,914
-25% -$418K
HTWR
94
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$1.14M 0.14%
+15,700
New +$1.23M
MTEM
95
DELISTED
Molecular Templates, Inc.
MTEM
$814K 0.1%
1,221
– –
BIND
96
DELISTED
BIND THERAPEUTICS INC
BIND
$746K 0.09%
133,535
– –
LGND icon
97
Ligand Pharmaceuticals
LGND
$6.36B
– –
-62,517
Closed -$3.01M
MYGN icon
98
Myriad Genetics
MYGN
$312M
– –
-60,000
Closed -$2.12M
SYK icon
99
Stryker
SYK
$130B
– –
-32,000
Closed -$2.95M
XLB icon
100
PUT
State Street Materials Select Sector SPDR ETF
XLB
$8.66B
– –
-880,000
Closed -$31.9M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Rhenman & Partners Asset Management held 103 positions worth $833M, up 40% from $593M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management deployed $158M of net new capital in Q2 2015, opening 14 new positions and adding to 42 existing holdings. Its largest new stake was Johnson & Johnson: 191,000 shares worth $18.6M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Amgen, an estimated $4.81M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2015 buy was Johnson & Johnson: 191,000 shares worth $18.6M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2015, an estimated $11.9M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2015 reduction was Amgen, cutting an estimated $4.81M.
  • Rhenman & Partners Asset Management fully exited OMNICARE INC in Q2 2015, selling an estimated $3.85M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $833M portfolio in Q2 2015.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 7 in Q2 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 40% quarter-over-quarter to $833M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2015, filed 30 Jul 2015.